External Control Arms in Japan: A Systematic Case Analysis of Documented Regulatory Implementation and Uncertainty...

Area of Science:

• Regulatory Science
• Clinical Trial Methodology
• Pharmaceutical Policy

Background:

• External control arms (ECAs) are vital for regulatory decision-making when randomized controlled trials are infeasible.
• The practical implementation, documentation, and uncertainty management of ECAs in regulatory approvals require clarification.

Purpose of the Study:

• To systematically evaluate the documentation and methodological rigor of ECAs used in Japanese regulatory approvals.
• To assess how residual uncertainty is managed post-approval when ECAs are employed.

Main Methods:

• Systematic screening of Japanese new medical product approvals (2019-2024) to identify ECA use.
• Evaluation of 23 identified ECA cases using a 20-attribute framework covering planning, selection, design, analysis, and reporting.
• Analysis of post-marketing requirements to understand residual uncertainty management.

Main Results:

• ECAs were primarily utilized for rare diseases and small patient populations.
• Study planning and data-source selection were generally well-documented, but design and analysis elements showed significant heterogeneity.
• Inconsistent specifications for estimands and handling of intercurrent events/missing data were noted.
• Post-marketing requirements frequently addressed residual uncertainty through efficacy studies and surveillance.

Conclusions:

• Opportunities exist to enhance transparency and consistency in documenting ECA-based evidence for regulatory submissions.
• Structured approaches to managing uncertainty throughout a product's lifecycle, informed by post-approval studies, are crucial.
• Further standardization in ECA methodology and reporting is recommended to support robust regulatory decision-making.